Martin Meyer

Title: Martin Meyer: Innovator in Retroviral Vector Production

Introduction

Martin Meyer is a notable inventor based in Kürten, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for producing retroviral vector particles. With a total of 3 patents to his name, Meyer continues to push the boundaries of scientific research and application.

Latest Patents

Meyer’s latest patents include groundbreaking inventions that enhance the production of viral vectors. One of his notable patents is the "LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof." This invention provides a method for producing VSV-G pseudotyped retroviral vector particles using a packaging cell line that is negative for Low-Density Lipoprotein Receptor (LDLR). The patent also describes a method for producing these particles, which are crucial for various therapeutic applications.

Another significant patent is the "Chimeric antigen receptor specific for BDCA2 antigen." This invention discloses a chimeric antigen receptor (CAR) that includes an antigen binding domain specific for BDCA2. The engineered cells expressing this CAR are designed for the treatment of cancers, particularly those where cancerous cells express BDCA2, such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Career Highlights

Martin Meyer is currently associated with Miltenyi Biotec B.V. & Co. KG, a leading company in the field of biotechnology. His work at Miltenyi Biotec has allowed him to collaborate with other experts in the field, further enhancing his contributions to innovative biotechnological solutions.

Collaborations

Meyer has worked alongside notable colleagues such as Andrzej Dzionek and Thomas Schaser. Their collaborative efforts have played a significant role in advancing research and development in the field of retroviral vectors.

Conclusion

Martin Meyer is a distinguished inventor whose work in retroviral vector production has made a substantial impact on biotechnology. His innovative patents and collaborations continue to pave the way for advancements in cancer treatment and gene therapy.